FINWIRES · TerminalLIVE
FINWIRES

Selkirk Copper Upsizes Private Placement of Shares to $30.0 Million

-- Selkirk Copper (SCMI.V) Friday said it upsized a bought-deal financing of shares by $10.0 million, to $30.0 million.

The company will now sell underwriters 4.4-million tax-advantaged flow-through shares at $1.70 each, to raise $7.5 million, and 19.6-million common shares priced at $1.15 each, to raise $22.5 million. The underwriters have also been granted an over-allotment option of 4.35 million common shares, which, if fully exercised would yield additional proceeds of $5.0 million.

Proceeds will be used to advance development of the Minto Mine in the Yukon.

The offering is expected to close on April 30.

Selkirk Copper shares were last seen down $0.04 to $1.31 on the TSX Venture Exchange.

Price: $1.32, Change: $-0.03, Percent Change: -2.22%

Related Articles

Asia

Beijing Enlight Media Q1 Profit Falls 99%; Shares Down 8%

Beijing Enlight Media Co (SHE:300251) posted first-quarter attributable net profit of 23.3 million yuan, down 99% from 2.02 billion yuan the previous year.Earnings per share went down to 0.01 yuan from 0.69 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue fell 94% year over year to 190.6 million yuan from 2.97 billion yuan.Shares of the media company were down 8% in recent trade.

$SHE:300251
Asia

Enlight Media 2025 Profit Jumps 473%; Shares Fall 7%

Beijing Enlight Media (SHE:300251) posted 2025 attributable net profit of 1.67 billion yuan, up 473% from 292.0 million yuan the previous year.Earnings per share went up to 0.57 yuan from 0.10 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue jumped 155% year over year to 4.04 billion yuan from 1.59 billion yuan.Shares of the media company were down 7% in recent trade.

$SHE:300251
Asia

CR Double-Crane Pharma Gets Nod to Name Unit as Marketer of Endometriosis Drug

China Resources Double-Crane Pharmaceutical (SHA:600062) received approval from the National Medical Products Administration to change the marketing authorization holder of dienogest tablets, according to a Shanghai bourse filing on Wednesday.Under the approved supplementary application, the pharmaceutical company's subsidiary, CR Zizhu Pharmaceutical, becomes the marketing authorization holder, as well as the manufacturer of the endometriosis drug.

$SHA:600062